Ranger™ and Ranger™ SL (OTW) DCB) in China
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 123 participants.
Also called NCT02944071
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 123 participants
- Sponsor
- Registry
-
NCT02944071
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02944071. Allocation not applicable; no masking; primary purpose treatment. Start 2016-11-24 (actual); primary completion 2020-12-22 (actual). Results posted on 2022-03-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ranger™ and Ranger™ SL (OTW) DCB) in China
- Condition
- Femoropopliteal Artery Lesions
- Intervention (Device)
- Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct02944071- Content hash
19119fd8d5fd1904ba70ba2b4b307544af93e3d9e965ed9fe4d7a39479d6a262